On January 12, 2022 Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, reported that pipeline and corporate updates at the 40th Annual J.P. Morgan Healthcare Conference (Press release, Precigen, JAN 12, 2022, View Source [SID1234605464]). Helen Sabzevari, PhD, President and CEO of Precigen, presented a summary of 2021 achievements and set forth Precigen’s goals for 2022.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Precigen’s presentation included the following pipeline announcements:
PRGN-3006 UltraCAR-T in Acute Myeloid Leukemia (AML)
Overview: PRGN-3006 is an investigational multigenic, autologous chimeric antigen receptor T cell (CAR-T) therapy engineered to simultaneously express a CAR specifically targeting CD33, membrane bound IL-15 (mbIL15), and a kill switch. PRGN-3006 UltraCAR-T is under evaluation in a Phase 1/1b clinical trial for the treatment of patients with relapsed or refractory AML or higher-risk myelodysplastic syndromes (MDS). Trial subjects receive the PRGN-3006 infusion either without prior lymphodepletion (Cohort 1) or following lymphodepleting chemotherapy (Cohort 2). PRGN-3006 UltraCAR-T has been granted Orphan Drug Designation in patients with AML by the FDA.
Program Updates: Precigen announced enrollment completion for Dose Level 3 of the lymphodepletion cohort. Interim data for patients treated in Dose Levels 1-3 of the non-lymphodepletion cohort and Dose Levels 1-2 of the lymphodepletion cohort were recently presented at the 63rd American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition. The dose escalation phase of the study is now complete for both the lymphodepletion and non-lymphodepletion cohorts and the Company plans to initiate a multicenter expansion phase of the study at Dose Level 3 with lymphodepletion in the first half of 2022. The Company plans to incorporate a repeat dosing regimen in the expansion phase. Additional Phase 1/1b data is expected in 2022.
PRGN-3005 UltraCAR-T in Ovarian Cancer
Overview: PRGN-3005 UltraCAR-T is an investigational multigenic, autologous CAR-T cell therapy engineered to express a CAR specifically targeting the unshed portion of MUC16, which is highly expressed on ovarian tumors with limited normal tissue expression, mbIL15, and a kill switch. PRGN-3005 UltraCAR-T is under evaluation in a Phase 1/1b clinical trial for the treatment of patients with advanced, recurrent platinum-resistant ovarian cancer. Trial subjects receive PRGN-3005 either via intraperitoneal (IP) (Arm A) or intravenous (IV) (Arm B) infusion.
Program Updates: Precigen announced enrollment completion for Dose Level 3 of the IV arm, completing enrollment in both the IP and IV arms in the dose escalation phase of the study. Interim data for patients treated in Dose Levels 1-3 of the IP arm were recently presented at the Company’s 2021 R&D Virtual Event. The Company has received FDA clearance to incorporate lymphodepletion at Dose Level 3 of the IV arm and will initiate the multicenter expansion phase of the study, incorporating redosing.
PRGN-3007 Next Generation UltraCAR-T with Intrinsic PD-1 Inhibition
Overview: PRGN-3007, based on the next generation of the UltraCAR-T platform, is an investigational multigenic, autologous CAR-T cell therapy engineered to simultaneously express a CAR targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), mbIL15, a kill switch, and a novel mechanism for the intrinsic blockade of PD-1 gene expression. ROR1 is aberrantly expressed in multiple hematological tumors, including chronic lymphocytic leukemia (CLL), mantle cell leukemia (MCL), acute lymphoblastic leukemia (ALL), and diffuse large B-cell lymphoma (DLBCL) and solid tumors, including breast adenocarcinomas such as triple negative breast cancer (TNBC), pancreatic cancer, ovarian cancer, and lung adenocarcinoma. ROR1 is minimally expressed in healthy adult tissues.
Program Updates: Precigen plans to initiate dosing in the Phase 1 study in ROR1+ hematological (CLL, MCL, ALL, DLBCL) and solid (TNBC) tumors in 2022.
PRGN-2012 AdenoVerse Immunotherapy in Recurrent Respiratory Papillomatosis (RRP)
Overview: PRGN-2012 is an investigational off-the-shelf (OTS) AdenoVerse immunotherapy designed to elicit immune responses directed against cells infected with HPV 6 or HPV 11 for treatment of RRP. PRGN-2012 is currently under evaluation in a Phase 1 clinical trial under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). The Phase 1 trial is designed to follow 3+3 dose escalation of PRGN-2012 as an adjuvant immunotherapy following standard-of-care surgical removal of visible papillomas in adult patients with RRP. PRGN-2012 has been granted Orphan Drug Designation in patients with RRP by the FDA.
Program Updates: Precigen announced enrollment completion for the Phase 1 dose escalation and expansion cohorts of the Phase 1 study. Interim data for the Phase 1 study were recently presented at the Company’s 2021 R&D Virtual Event. The Company plans to seek FDA guidance on a rapid regulatory strategy for PRGN-2012 in RRP given the positive interim results and significant unmet patient need. Additional Phase 1 expansion data is expected in the second half of 2022.
PRGN-2009 AdenoVerse Immunotherapy in HPV-associated Cancers
Overview: PRGN-2009 is an OTS investigational immunotherapy utilizing the AdenoVerse platform designed to activate the immune system to recognize and target HPV-positive (HPV+) solid tumors. PRGN-2009 is currently under evaluation in a Phase 1/2 clinical trial under a CRADA with the NCI. The Phase 1 trial is evaluating safety and response of PRGN-2009 as a monotherapy (Arm A) and in combination with M7824 (Arm B) in previously treated patients with recurrent or metastatic HPV-associated cancers.
Program Updates: Precigen announced enrollment completion in the Phase 1 monotherapy arm. Enrollment is ongoing in the Phase 1 combination arm and the Phase 2 monotherapy arm in newly diagnosed OPSCC patients. Interim data for patients in the Phase 1 monotherapy and combination arms treated at Dose Levels 1-2 were recently presented at the Company’s 2021 R&D Virtual Event. Additional Phase 1 data for both arms is expected in 2022. The Company plans to seek FDA guidance on a rapid regulatory strategy for PRGN-2009 given the positive interim results and significant unmet patient need. The Company also plans to initiate a Phase 2 study in advanced HPV-associated cancer indications in combination with an approved anti-PD-1 checkpoint inhibitor.
AG019 ActoBiotics
Overview: AG019 is an investigational therapy designed to induce oral immune tolerance to reverse type 1 diabetes (T1D) and is currently under clinical evaluation for the treatment of early-onset T1D.The Phase 1b/2a clinical trial is evaluating AG019 as a monotherapy and in combination with teplizumab (PRV-031), which is currently under investigation in the PROTECT Phase 3 study for the treatment of newly diagnosed T1D.
Program Updates: Precigen announced the completion of the Phase 1b/2a clinical trial. Positive results from the trial were presented last year at the Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting and European Association for the Study of Diabetes (EASD) 57th Annual Meeting. The Company plans to initiate discussions with the FDA and European Medicines Agency (EMA) for Phase 2/3 clinical trial design for AG019 in T1D.
"Precigen made significant clinical progress in 2021 across our pipeline programs. We were able to meet the major clinical goals we outlined at JPM last year, and exceeded some goals such as the rapid progress made for PRGN-2012 in RRP. Interim data presented in 2021 across three platforms – UltraCAR-T, AdenoVerse, ActoBiotics – and five clinical programs continue to produce positive results" said Helen Sabzevari, PhD, President and CEO of Precigen, "In 2022, we will continue to advance our clinical programs with a concentration on rapid paths to licensure for programs addressing high unmet patient needs."
Precigen’s J.P. Morgan presentation is available on the Company website in the Events & Presentations section at investors.precigen.com/events-presentations.